isatin has been researched along with Hepatocellular Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, Y; Bian, W; Qu, H; Xu, Y; Yang, J; Yang, Y | 1 |
| Cao, L; Zhang, L; Zhang, Y; Zhao, X | 1 |
2 other study(ies) available for isatin and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Allyl-isatin suppresses cell viability, induces cell cycle arrest, and promotes cell apoptosis in hepatocellular carcinoma HepG2 cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Survival; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Isatin; Liver Neoplasms; Monoamine Oxidase Inhibitors | 2016 |
A Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma Cells.
Topics: Antineoplastic Agents; Apoptosis; Bibenzyls; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Chalcone; Cytoskeleton; Focal Adhesions; Hep G2 Cells; Humans; Isatin; Liver Neoplasms; Molecular Targeted Therapy; Oncogene Proteins; Paxillin; Protein Multimerization; Protein Structure, Quaternary; Tubulin; Vacuoles; Wnt Signaling Pathway | 2016 |